Presented
at the World Diabetes Congress in Dubai, the new study has indicated there is
no relationship between the use of Lantus and an increased cancer risk,
following an assessment of various different insulins.
The research drew data from observational studies derived from databases plus randomised, controlled clinical trials and a case-control study in numerous countries, including England, Scotland, Sweden, Germany and Taiwan.
According to researchers, the data from this study can be considered more conclusive due to the multitude of sources from which the results were taken.
Dr Jean-Pierre Lehner, chief medical officer at Sanofi, said: "We welcome the coherence of these new data, which reinforce the clinical profile of Lantus, one of the most studied treatments in the management of diabetes."
Last month, the company attended the Pan African Conference against Malaria, where it outlined the work it has undertaken to combat the disease in recent years.
The research drew data from observational studies derived from databases plus randomised, controlled clinical trials and a case-control study in numerous countries, including England, Scotland, Sweden, Germany and Taiwan.
According to researchers, the data from this study can be considered more conclusive due to the multitude of sources from which the results were taken.
Dr Jean-Pierre Lehner, chief medical officer at Sanofi, said: "We welcome the coherence of these new data, which reinforce the clinical profile of Lantus, one of the most studied treatments in the management of diabetes."
Last month, the company attended the Pan African Conference against Malaria, where it outlined the work it has undertaken to combat the disease in recent years.